par Van Antwerpen, Pierre 
;Prévost, Martine ;Zouaoui Boudjeltia, Karim ;Babar, Sajida ;Legssyer, Ilham ;Moreau, Patrick ;Moguilevsky, Nicole ;Vanhaeverbeek, Michel ;Ducobu, Jean ;Neve, Jean ;Dufrasne, François
Référence Bioorganic & medicinal chemistry, 16, 4, page (1702-1720)
Publication Publié, 2008-02
;Prévost, Martine ;Zouaoui Boudjeltia, Karim ;Babar, Sajida ;Legssyer, Ilham ;Moreau, Patrick ;Moguilevsky, Nicole ;Vanhaeverbeek, Michel ;Ducobu, Jean ;Neve, Jean ;Dufrasne, François Référence Bioorganic & medicinal chemistry, 16, 4, page (1702-1720)
Publication Publié, 2008-02
Article révisé par les pairs
| Résumé : | The development of myeloperoxidase (MPO) inhibitors has been conducted using flufenamic acid as a lead compound. Computational docking of the drug and its analogs in the MPO active site was first attempted. Several molecules were then synthesized and assessed using three procedures for the measurement of their inhibiting activity: (i) the taurine assay, (ii) the accumulation of compound II, and (iii) the LDL oxidation by ELISA. Most of the synthesized molecules had an activity in the same range as flufenamic acid but none of them were able to inhibit the MPO-dependent LDL oxidation. The experiments however gave some useful indications for a rational conception of MPO inhibitors. © 2007 Elsevier Ltd. All rights reserved. |
